Market research
ABEO Abeona Therapeutics Inc
NASDAQ USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 246M
- P/E ratio
- Not available
- Analyst target
- 18.875
- Dividend yield
- Not available
- Beta
- 1.3
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 246M
- P/E ratio
- Not available
- Analyst target
- 18.875
- Dividend yield
- Not available
- Beta
- 1.3
About
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Research context
Abeona Therapeutics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ABEO discussion.
5 years, 6 months ago
Abeona Therapeutics Inc is currently in a long term downtrend where the price is trading 13.0% below its 200 day moving average.
From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.1.
Abeona Therapeutics Inc's total revenue rose by inf% to $3M since the same quarter in the previous year.
Its net income has increased by 3.7% to $-16M since the same quarter in the previous year.
Finally, its free cash flow grew by 88.6% to $-2M since the same quarter in the previous year.
Based on the above factors, Abeona Therapeutics Inc gets an overall score of 4/5.